George D Demetri
Overview
Explore the profile of George D Demetri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
229
Citations
21076
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pimenta E, Garza A, Camp S, Park J, Hoffman S, Valderrabano L, et al.
bioRxiv
. 2025 Feb;
PMID: 39896505
Sarcomas are rare connective tissue cancers thought to arise from aberrant mesenchymal stem cell (MSC) differentiation. Liposarcoma (LPS) holds valuable insights into dysfunctional differentiation given its well- and dedifferentiated histologic...
2.
Rodriguez L, Gormley N, Lu R, Amatya A, Demetri G, Flaherty K, et al.
Clin Cancer Res
. 2024 Jul;
30(18):3974-3982.
PMID: 39037364
Advances in anticancer therapies have provided crucial benefits for millions of patients who are living long and fulfilling lives. Although these successes should be celebrated, there is certainly room to...
3.
Cote G, Haddox C, Choy E, Merriam P, Mazzola E, Venkataraman V, et al.
Clin Cancer Res
. 2024 May;
30(13):2702-2708.
PMID: 38723278
Purpose: While cytotoxic chemotherapy is the standard first-line treatment for patients with metastatic soft-tissue sarcoma (STS), clinical outcomes remain suboptimal. Our prior study showed lurbinectedin plus doxorubicin is well tolerated...
4.
DAngelo S, Araujo D, Abdul Razak A, Agulnik M, Attia S, Blay J, et al.
Lancet
. 2024 Mar;
403(10435):1460-1471.
PMID: 38554725
Background: Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising efficacy in a phase 1 trial (NCT03132922). The aim of this study was to further evaluate the efficacy of afami-cel for...
5.
Heinrich M, Corless C, Demetri G, Blanke C, von Mehren M, Joensuu H, et al.
J Clin Oncol
. 2023 Oct;
41(31):4829-4836.
PMID: 37890277
Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The...
6.
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Kummar S, Shen L, Hong D, McDermott R, Keedy V, Casanova M, et al.
Cancer
. 2023 Sep;
129(23):3772-3782.
PMID: 37769113
Background: Larotrectinib, a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with various solid tumors harboring NTRK gene fusions. This subset analysis...
7.
Bevill S, Casani-Galdon S, El Farran C, Cytrynbaum E, Macias K, Oldeman S, et al.
Cell Genom
. 2023 Jul;
3(7):100321.
PMID: 37492096
Amplification of MDM2 on supernumerary chromosomes is a common mechanism of P53 inactivation across tumors. Here, we investigated the impact of MDM2 overexpression on chromatin, gene expression, and cellular phenotypes...
8.
Schaefer I, Hemming M, Lundberg M, Serrata M, Goldaracena I, Liu N, et al.
Br J Cancer
. 2022 Sep;
127(11):2072-2085.
PMID: 36175617
Background: Advanced gastrointestinal stromal tumour (GIST) is characterised by genomic perturbations of key cell cycle regulators. Oncogenic activation of CDK4/6 results in RB1 inactivation and cell cycle progression. Given that...
9.
Gyurdieva A, Zajic S, Chang Y, Houseman E, Zhong S, Kim J, et al.
Nat Commun
. 2022 Sep;
13(1):5296.
PMID: 36075914
Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic synovial sarcoma, with 50% overall response...
10.
Stacchiotti S, Frezza A, Demetri G, Blay J, Bajpai J, Baldi G, et al.
Cancer Treat Rev
. 2022 Aug;
110:102455.
PMID: 36031697
Background: In ultra-rare sarcomas (URS) the conduction of prospective, randomized trials is challenging. Data from retrospective observational studies (ROS) may represent the best evidence available. ROS implicit limitations led to...